ImpediMed Limited (ASX:IPD)
has entered into an agreement with the Harvard Clinical Research Institute located in Boston, Massachusetts to advance research around BIS in fluid detection.
Initial activities under the agreement include organising and managing a medical advisory board to assess the use of BIS in chronic heart failure patients.
ImpediMed specialises in providing technology to measure, monitor and manage fluid status and body composition.
The company says it believes its BIS technology could provide a cost effective solution for better management of fluid detection and accumulation in chronic disease management.
ImpediMed Limited reported a net loss of $14.8 million at 30 June 2015.